Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Treated With Lyrica

NCT00541476 | Completed

• 1 other identifier: A0081178
• Study Type: observational
• Target: 746
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to obtain more data about efficacy and safety of the study drug Lyrica.

Conditions

Neuralgia

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinical diagnosis of peripheral or central neuropathic pain

You may not qualify if:

• None. Patients recruited by physician decision. Patient's personal data are not collected.

Sponsors & Collaborators

• Pfizer's Upjohn has merged with Mylan to form Viatris Inc.: lead

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Neuralgia

Condition Hierarchy (Ancestors)

Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 8, 2007
• First Posted: October 10, 2007
• Study Start: June 1, 2007
• Primary Completion: December 1, 2007
• Study Completion: December 1, 2007
• Last Updated: January 22, 2021

Record last verified: 2008-11